Brentuximab vedotin and ESHAP is highly effective as second-line therapy for Hodgkin lymphoma patients (long-term results of a trial by the Spanish GELTAMO Group)Ramón García‐Sánz, Carmen Martı́nez, Fátima De la Cruz et al.|Annals of Oncology|2019Cited by 129